NNK activates ERK1/2 and CREB/ATF-1 via β-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells

International Journal of Cancer

Volumn 119, Issue 7, 2006, Pages 1547-1552

  Laag, E ^a   Majidi, M ^a   Cekanova, M ^a   Masi, T ^a   Takahashi, T ^b   Schuller, H M ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1 AR; EGFR; Pulmonary adenocarcinoma; Small airway epithelia; Transactivation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ACTIVATING TRANSCRIPTION FACTOR 1; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITROSAMINE; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CLARA CELL; CONTROLLED STUDY; DNA SYNTHESIS; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; LUNG ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RECEPTOR GENE; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CELL LINE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA; DNA-BINDING PROTEINS; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; NITROSAMINES; NUCLEAR PROTEINS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 33747450166     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21987     Document Type: Article

References (28)

1. Kelly A, Blair N, Pechacek TF. Women and smoking: issues and opportunities. J Womens Health Gend Based Med 2001;10:515-18.
2. Burns DM. Tobacco-related diseases. Semin Oncol Nurs 2003;19:244-9.
3. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
4. Levi F, Franceschi S, La Vecchia C, Randimbison L, Te VC. Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer 1997;79:906-14.
5. Linnoila I. Pathology of non-small cell lung cancer. New diagnostic approaches. Hematol Oncol Clin North Am 1990;4:1027-51.
6. Wynder EL, Muscat JE. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995;103 (Suppl 8):143-8.
7. Belinsky SA, Devereux TR, White CM, Foley JF, Maronpot RR, Anderson MW. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res 1991;17:263-78.
8. Hoffmann D, Rivenson A, Chung FL, Hecht SS. Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. Crit Rev Toxicol 1991;21:305-11.
9. Schuller HM, Witschi HP, Nylen E, Joshi PA, Correa E, Becker KL. Pathobiology of lung tumors induced in hamsters by 4-(methylnitros-amino)-1-(3- pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res 1990;50:1960-5.
10. Hecht SS. Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit Rev Toxicol 1996;26:163-81.
11. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6:1353-62.
12. Belinsky SA, Devereux TR, Maronpot RR, Stoner GD, Anderson MW. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 1989;49:5305-11.
13. Oreffo VI, Lin HW, Padmanabhan R, Witschi H. K-ras and p53 point mutations in4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. Carcinogenesis 1993;14:451-5.
14. Schuller HM, Tithof PK, Williams M, Plummer H, III. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a β-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via β-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 1999;59:4510-15.
15. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002;2:455-63.
16. Schuller HM, Porter B, Riechert A. β-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 2000;126:624-30.
17. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM. The β(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000;275:9572-80.
18. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
19. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001;20:1532-9.
20. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-60.
21. Hu LA, Chen W, Martin NP, Whalen EJ, Premont RT, Lefkowitz RJ. GIPC interacts with the β1-adrenergic receptor and regulates β1-adrenergic receptor-mediated ERK activation. J Biol Chem 2003;278:26295-301.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
23. Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
24. Murphy LO, Cluck MW, Lovas S, Otvos F, Murphy RF, Schally AV, Permert J, Larsson J, Knezetic JA, Adrian TE. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer 2001;84:926-35.
25. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004;90:1047-52.
26. Kim J, Eckhart AD, Eguchi S, Koch WJ. β-adrenergic receptor mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 2002;277:32116-23.
27. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X, Bertherat J. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann NY Acad Sci 2002;968:65-74.
28. 2-adrenergic and EGFR signaling pathways. Lung Cancer 2006;49:35-45.